Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Toripalimab, a therapeutic monoclonal anti-PD-1 antibody with high binding affinity to PD-1 and enhanced potency to activate human T cells
Narendiran Rajasekaran, Xiaoguang Wang, Sruthi Ravindranathan, et al.
Cancer Immunology Immunotherapy (2024) Vol. 73, Iss. 3
Open Access | Times Cited: 9

Showing 9 citing articles:

The combination of immune checkpoint inhibitors and antibody-drug conjugates in the treatment of urogenital tumors: a review insights from phase 2 and 3 studies
Puguang Yu, Chunming Zhu, Xiangyun You, et al.
Cell Death and Disease (2024) Vol. 15, Iss. 6
Open Access | Times Cited: 8
Predictive Biomarkers and Resistance Mechanisms of Checkpoint Inhibitors in Malignant Solid Tumors
Luciana Alexandra Pavelescu, Robert Mihai Enache, Oana Alexandra Roşu, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 17, pp. 9659-9659
Open Access | Times Cited: 5
Immuno-oncological Challenges and Chemoresistance in Veterinary Medicine: Probiotics as a New Strategic Tool
Muhammad Nisar, Tingdong Yan, Yi Cai, et al.
Probiotics and Antimicrobial Proteins (2025)
Closed Access
Toripalimab Plus Chemotherapy as a First-Line Therapy for Extensive-Stage Small Cell Lung Cancer
Ying Cheng, Wei Zhang, Lin Wu, et al.
JAMA Oncology (2024) Vol. 11, Iss. 1, pp. 16-16
Closed Access | Times Cited: 4
Are all programmed cell death protein 1 inhibitors the same?
Jochen H. Lorch, Stacey Stein, Martin J. Edelman
Frontiers in Oncology (2025) Vol. 15
Open Access
Cost-efficiency and budget-neutral expanded access modeling of pembrolizumab versus the novel PD-1 inhibitor toripalimab in locally advanced or metastatic nonsquamous non-small cell lung cancer
Karen MacDonald, Marc Pondel, Ivo Abraham
Journal of Medical Economics (2024) Vol. 27, Iss. sup3, pp. 24-33
Open Access | Times Cited: 2
Role of PD-1/PD-L1 signaling axis in oncogenesis and its targeting by bioactive natural compounds for cancer immunotherapy
Yogesh Godiyal, Drishti Maheshwari, Hiroaki Taniguchi, et al.
Military Medical Research (2024) Vol. 11, Iss. 1
Open Access | Times Cited: 1
Toripalimab For Extensive-Stage Small Cell Lung Cancer
Ayse Ece Cali Daylan, Daniel Morgensztern, Saiama N. Waqar
JAMA Oncology (2024)
Closed Access
Budget impact analysis of pembrolizumab versus the novel PD-1 inhibitor toripalimab in locally advanced or metastatic nonsquamous non-small cell lung cancer
Ivo Abraham, Matthias Calamia, Nimer S. Alkhatib, et al.
Journal of Medical Economics (2024) Vol. 27, Iss. sup3, pp. 36-50
Open Access
Page 1

Scroll to top